Search

Your search keyword '"Machado–Joseph disease"' showing total 194 results

Search Constraints

Start Over You searched for: Descriptor "Machado–Joseph disease" Remove constraint Descriptor: "Machado–Joseph disease" Database Complementary Index Remove constraint Database: Complementary Index
194 results on '"Machado–Joseph disease"'

Search Results

1. Aboriginal families living with MJD in remote Australia: questions of access and equity.

2. Specific Biomarkers in Spinocerebellar Ataxia Type 3: A Systematic Review of Their Potential Uses in Disease Staging and Treatment Assessment.

3. Progression of Retinal Ganglion Cell and Nerve Fiber Layer Loss in Spinocerebellar Ataxia 3 Patients.

4. "I Do Not Know How You Feel and How I Feel About That": Mentalizing Impairments in Machado-Joseph Disease.

5. Production of Spinocerebellar Ataxia Type 3 Model Mice by Intravenous Injection of AAV-PHP.B Vectors.

6. Functional impact of bilateral vestibular loss and the unexplained complaint of oscillopsia.

7. Genetic Epidemiology and Clinical Characteristics of Patients with Spinocerebellar Ataxias in an Unexplored Brazilian State, Using Strategies for Resource-Limited Settings.

8. Spermidine treatment: induction of autophagy but also apoptosis?

9. The vestibular symptomatology of Machado-Joseph Disease.

10. Machado Joseph-Disease Is Rare in the Peruvian Population.

11. A model for the dynamics of expanded CAG repeat alleles: ATXN2 and ATXN3 as prototypes.

12. Mitochondrial Dysfunction and Decreased Cytochrome c in Cell and Animal Models of Machado–Joseph Disease.

13. Voxel-Based Morphometry and Relaxometry Demonstrate Macro- and Microstructural Damages in Spinocerebellar Ataxia Type 3.

14. Genetic Ablation of Inositol 1,4,5-Trisphosphate Receptor Type 2 (IP 3 R2) Fails to Modify Disease Progression in a Mouse Model of Spinocerebellar Ataxia Type 3.

15. Diagnostic Delay of Hereditary Ataxias in Brazil: the Case of Machado-Joseph Disease.

16. Regional and age-dependent changes in ubiquitination in cellular and mouse models of spinocerebellar ataxia type 3.

17. Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics.

18. Gene Suppression Therapies in Hereditary Cerebellar Ataxias: A Systematic Review of Animal Studies.

19. Autophagic vacuolar myopathy involving the phenotype of spinocerebellar ataxia type 3.

20. Disease-associated oligodendrocyte signatures are spatiotemporally dysregulated in spinocerebellar ataxia type 3.

21. Progression of Clinical and Eye Movement Markers in Preataxic Carriers of Machado‐Joseph Disease.

22. A Young Japanese Patient with Spinocerebellar Ataxia Type 3 Presenting Depressive State with Cenesthopathy and Delusion: a Case Report.

23. Designing augmentative and alternative communication systems with Aboriginal Australians: vocabulary representation, layout, and access.

24. Augmentative and alternative communication for Aboriginal Australians: Developing core vocabulary for Yolŋu speakers.

25. Pathogenetic Mechanisms Underlying Spinocerebellar Ataxia Type 3 Are Altered in Primary Oligodendrocyte Culture.

26. Altered glucose metabolism and its association with carbonic anhydrase 8 in Machado-Joseph Disease.

27. The neostriatum in polyglutamine diseases: preferential decreases in large neurons in dentatorubral‐pallidoluysian atrophy and Machado‐Joseph disease and in small neurons in Huntington disease.

28. Microglial Depletion Has No Impact on Disease Progression in a Mouse Model of Machado–Joseph Disease.

29. Mitochondrial Dysfunction in Spinocerebellar Ataxia Type 3 Is Linked to VDAC1 Deubiquitination.

30. Quality of Life since Pre-Ataxic Phases of Spinocerebellar Ataxia Type 3/Machado–Joseph Disease.

31. Impaired Oligodendrocyte Maturation Is an Early Feature in SCA3 Disease Pathogenesis.

32. A Variant in Genes of the NPY System as Modifier Factor of Machado-Joseph Disease in the Chinese Population.

33. The autophagy‐enhancing drug carbamazepine improves neuropathology and motor impairment in mouse models of Machado–Joseph disease.

34. Identification of the calpain‐generated toxic fragment of ataxin‐3 protein provides new avenues for therapy of Machado–Joseph disease| Spinocerebellar ataxia type 3.

35. A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes.

36. Pathophysiological interplay between O-GlcNAc transferase and the Machado-Joseph disease protein ataxin-3.

37. Between responsibility and desire: Accounts of reproductive decisions from those at risk for or affected by late‐onset neurological diseases.

38. Variants in Genes of Calpain System as Modifiers of Spinocerebellar Ataxia Type 3 Phenotype.

39. Reports on Machado-Joseph Disease Findings from National University Hospital Provide New Insights [Preimplantation Genetic Testing of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease-Robust Tools for Direct and Indirect Detection of the...].

40. Researchers from James Cook University Provide Details of New Studies and Findings in the Area of Machado-Joseph Disease (Feasibility and impact of a physical activity and lifestyle program for Aboriginal families with Machado-Joseph disease in...).

41. Studies from Tel Aviv University Reveal New Findings on Machado-Joseph Disease (The Vestibular Symptomatology of Machado-joseph Disease).

42. Mutant Ataxin-3–Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.

43. Small Molecule Rescue of ATXN3 Toxicity in C. elegans via TFEB/HLH-30.

44. Selective forces acting on spinocerebellar ataxia type 3/Machado–Joseph disease recurrency: A systematic review and meta‐analysis.

45. Which Factors in Spinocerebellar Ataxia Type 3 Patients Are Associated with Restless Legs Syndrome/Willis-Ekbom Disease?

46. Corticospinal tract involvement in spinocerebellar ataxia type 3: a diffusion tensor imaging study.

47. Yolŋu with Machado–Joseph disease: Exploring communication strengths and needs.

48. Trehalose in Machado-Joseph Disease: Safety, Tolerability, and Efficacy.

49. In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3.

50. Familial spontaneous pneumothorax and Machado–Joseph disease.

Catalog

Books, media, physical & digital resources